Vertex Pharmaceuticals Forecast, price target & analysts
Vertex Pharmaceuticals Target price 2025 - Analyst rating & recommendation
Vertex Pharmaceuticals Classifications & Recommendation:
Vertex Pharmaceuticals Price Target
| Target Price | $487.56 |
| Price | $416.81 |
| Potential | 16.97% |
| Number of Estimates | 29 |
| 29 Analysts have issued a price target Vertex Pharmaceuticals 2026 . The average Vertex Pharmaceuticals target price is $487.56. This is 16.97% higher than the current stock price. The highest price target is $655.20 57.19% , the lowest is $333.30 20.04% . | |
| A rating was issued by 39 analysts: 25 Analysts recommend Vertex Pharmaceuticals to buy, 13 to hold and 1 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the Vertex Pharmaceuticals stock has an average upside potential 2026 of 16.97% . Most analysts recommend the Vertex Pharmaceuticals stock at Purchase. |
Sales and Margin forecast 2025, 2026 to 2032
35 Analysts have issued a sales forecast Vertex Pharmaceuticals 2025 . The average Vertex Pharmaceuticals sales estimate is $12.2b . This is 7.05% higher than the revenue of the last 12 months(TTM). The highest sales forecast is $12.7b 11.58% , the lowest is $11.6b 1.60% .
This results in the following potential growth metrics:
Revenue Estimates
| 2024 | $11.0b | 11.66% |
|---|---|---|
| 2025 | $12.2b | 10.92% |
| 2026 | $13.4b | 9.55% |
| 2027 | $14.6b | 9.03% |
| 2028 | $15.9b | 8.97% |
| 2029 | $17.5b | 10.29% |
| 2030 | $19.2b | 9.18% |
| 2031 | $19.9b | 3.93% |
| 2032 | $21.5b | 7.91% |
14 Analysts have issued an Vertex Pharmaceuticals EBITDA forecast 2025. The average Vertex Pharmaceuticals EBITDA estimate is $5.5b . This is 19.82% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $6.1b 32.58% , the lowest is $4.5b 2.57% .
This results in the following potential growth metrics and future EBITDA Margins:
EBITDA Estimates
| 2024 | $4.6b | 1.37% |
|---|---|---|
| 2025 | $5.5b | 20.45% |
| 2026 | $6.6b | 19.72% |
| 2027 | $7.3b | 9.64% |
| 2028 | $7.5b | 3.08% |
| 2029 | $8.2b | 8.72% |
| 2030 | $8.9b | 8.72% |
| 2031 | $9.5b | 7.04% |
| 2032 | $11.3b | 19.21% |
EBITDA Margin
| 2024 | 41.77% | 9.21% |
|---|---|---|
| 2025 | 45.35% | 8.58% |
| 2026 | 49.56% | 9.28% |
| 2027 | 49.84% | 0.56% |
| 2028 | 47.15% | 5.40% |
| 2029 | 46.48% | 1.42% |
| 2030 | 46.28% | 0.43% |
| 2031 | 47.66% | 2.98% |
| 2032 | 52.66% | 10.49% |
36 Vertex Pharmaceuticals Analysts have issued a net profit forecast 2025. The average Vertex Pharmaceuticals net profit estimate is $4.7b . This is 29.69% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is $5.1b 39.31% , the lowest is $4.3b 17.18% .
This results in the following potential growth metrics and future Net Margins:
Net Profit Estimates
| 2024 | $-536m | 114.80% |
|---|---|---|
| 2025 | $4.7b | 980.78% |
| 2026 | $5.3b | 12.95% |
| 2027 | $5.9b | 9.93% |
| 2028 | $6.5b | 10.35% |
| 2029 | $7.3b | 13.43% |
| 2030 | $7.9b | 7.97% |
| 2031 | $8.6b | 8.40% |
| 2032 | $9.6b | 12.43% |
Net Margin
| 2024 | -4.86% | 113.25% |
|---|---|---|
| 2025 | 38.59% | 894.00% |
| 2026 | 39.79% | 3.11% |
| 2027 | 40.12% | 0.83% |
| 2028 | 40.62% | 1.25% |
| 2029 | 41.78% | 2.86% |
| 2030 | 41.32% | 1.10% |
| 2031 | 43.10% | 4.31% |
| 2032 | 44.91% | 4.20% |
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
36 Analysts have issued a Vertex Pharmaceuticals forecast for earnings per share. The average Vertex Pharmaceuticals EPS is $18.41 . This is 31.13% higher than earnings per share in the financial year 2024. The highest EPS forecast is $19.77 40.81% , the lowest is $16.63 18.45% .
This results in the following potential growth metrics and future valuations:
Earnings Per Share
| 2024 | $-2.08 | 114.97% |
|---|---|---|
| 2025 | $18.41 | 985.10% |
| 2026 | $20.79 | 12.93% |
| 2027 | $22.85 | 9.91% |
| 2028 | $25.22 | 10.37% |
| 2029 | $28.60 | 13.40% |
| 2030 | $30.88 | 7.97% |
| 2031 | $33.48 | 8.42% |
| 2032 | $37.64 | 12.43% |
P/E ratio
| Current | 29.10 | 111.06% |
|---|---|---|
| 2025 | 22.20 | 23.72% |
| 2026 | 19.65 | 11.49% |
| 2027 | 17.88 | 9.01% |
| 2028 | 16.20 | 9.40% |
| 2029 | 14.28 | 11.85% |
| 2030 | 13.23 | 7.35% |
| 2031 | 12.20 | 7.79% |
| 2032 | 10.86 | 10.98% |
Based on analysts' sales estimates for 2025, the Vertex Pharmaceuticals stock is valued at an EV/Sales of 8.05 and an P/S ratio of 8.57 .
This results in the following potential growth metrics and future valuations:
EV/Sales
| Current | 8.62 | 22.20% |
|---|---|---|
| 2025 | 8.05 | 6.63% |
| 2026 | 7.35 | 8.71% |
| 2027 | 6.74 | 8.28% |
| 2028 | 6.18 | 8.23% |
| 2029 | 5.61 | 9.33% |
| 2030 | 5.14 | 8.41% |
| 2031 | 4.94 | 3.78% |
| 2032 | 4.58 | 7.33% |
P/S ratio
| Current | 9.17 | 21.47% |
|---|---|---|
| 2025 | 8.57 | 6.59% |
| 2026 | 7.82 | 8.71% |
| 2027 | 7.18 | 8.28% |
| 2028 | 6.58 | 8.23% |
| 2029 | 5.97 | 9.33% |
| 2030 | 5.47 | 8.41% |
| 2031 | 5.26 | 3.78% |
| 2032 | 4.88 | 7.33% |
Vertex Pharmaceuticals...
Current Vertex Pharmaceuticals Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Morgan Stanley |
Equal-Weight
➜
Equal-Weight
|
Unchanged | Oct 10 2025 |
| JP Morgan |
Overweight
➜
Overweight
|
Unchanged | Oct 08 2025 |
| Citigroup |
Buy
➜
Buy
|
Unchanged | Oct 02 2025 |
| Leerink Partners |
Market Perform
➜
Outperform
|
Upgrade | Sep 25 2025 |
| Evercore ISI Group |
Outperform
➜
Outperform
|
Unchanged | Sep 11 2025 |
| Raymond James |
➜
Market Perform
|
Initiated | Sep 03 2025 |
| Guggenheim |
Buy
➜
Buy
|
Unchanged | Aug 06 2025 |
| Analyst Rating | Date |
|---|---|
|
Unchanged
Morgan Stanley:
Equal-Weight
➜
Equal-Weight
|
Oct 10 2025 |
|
Unchanged
JP Morgan:
Overweight
➜
Overweight
|
Oct 08 2025 |
|
Unchanged
Citigroup:
Buy
➜
Buy
|
Oct 02 2025 |
|
Upgrade
Leerink Partners:
Market Perform
➜
Outperform
|
Sep 25 2025 |
|
Unchanged
Evercore ISI Group:
Outperform
➜
Outperform
|
Sep 11 2025 |
|
Initiated
Raymond James:
➜
Market Perform
|
Sep 03 2025 |
|
Unchanged
Guggenheim:
Buy
➜
Buy
|
Aug 06 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
